Compare AUROW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | SCLXW |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 1800 | 30 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | AUROW | SCLXW |
|---|---|---|
| Price | $0.24 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 137.0K | 4.0K |
| Earning Date | 04-30-2025 | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $2.09 | $0.18 |
| 52 Week High | $3.00 | $0.18 |
| Indicator | AUROW | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 29.07 | 35.78 |
| Support Level | $0.28 | $0.07 |
| Resistance Level | $0.30 | $0.19 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 31.85 |
Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.